Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genvoya PK for On-demand PEP
NCT03976752Phase 1Completed
- Sponsor
- Emory University
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Emory University. Primary endpoints: Plasma Concentration of Tenofovir at 96 hours, Plasma Concentration of Emtricitabine at 96 hours and 1 more. Started Mar 2019; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03976752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976752.